Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends and Growth Analysis 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Industry Compare Between 2025 And 2029?

The cell and gene therapy contract development and manufacturing organization (cdmo) market has experienced substantial expansion in recent years. Its valuation is anticipated to climb from $5.41 billion in 2024 to $6.92 billion in 2025, reflecting a compound annual growth rate (CAGR) of 27.9%. The growth observed in the preceding period can be linked to elevated technological advancements, supportive regulatory structures, increased financial investment, a high prevalence of genetic disorders, and an increasing number of strategic alliances.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is projected to undergo substantial expansion over the next few years. It is predicted to reach $17.57 billion in 2029, growing at a compound annual growth rate (CAGR) of 26.2%. The anticipated increase during this period can be ascribed to a wider range of therapeutic applications, evolving regulatory frameworks, greater financial input, advancements in technology, and increased international cooperation. Significant developments anticipated in the forecast period include a heightened demand for personalized treatments, an increase in automation and digital adoption, the expansion of production capabilities, the development of new delivery mechanisms, and a stronger emphasis on environmental sustainability and impact.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Which Drivers Are Shaping The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Industry’s Market Share?

The rising incidence of cancer cases is anticipated to drive the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market moving forward. This group of diseases is defined by the uncontrolled proliferation and spread of abnormal cells within the body. The increasing prevalence of cancer diagnoses is attributed to factors such as aging populations, evolving lifestyle habits, environmental exposures, and enhanced detection methods. The cell and gene therapy contract development and manufacturing organization (CDMO) aids in reducing cancer prevalence by developing and manufacturing innovative, targeted treatments that improve efficacy and patient outcomes. As an illustration, in October 2022, information from Macmillan Cancer Support, a UK-based charitable organization, indicated that the estimated number of individuals living with cancer in the UK is expected to climb from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the increasing occurrence of cancer cases propels the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

What Are The Major Segment Types Covered In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The cell and gene therapy contract development and manufacturing organization (cdmo)market covered in this report is segmented –

1) By Product Type: Gene Therapy; Gene-Modified Cell Therapy; Cell Therapy

2) By Phase: Phase 1; Phase 2; Phase 3; Phase 4

3) By Indication: Oncology; Infectious Diseases; Neurological Disorders; Rare Diseases; Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Gene Therapy; Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy; TCR-T Cell Therapy; NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy; Progenitor Cell Therapy; Immune Cell Therapy

Which Market Trends Are Creating New Opportunities In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Industry?

Leading companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are focused on expanding their offerings with advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of manufacturing cell-based products. PluriMatrix technology is a proprietary system specifically designed for the large-scale production of cell-based products. This advanced technology facilitates the 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division that provides cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). The new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division offers end-to-end services from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to offer advanced cell therapy manufacturing services.

Which Global Market Leaders Are Shaping The Future Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Sector?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

How Is Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Demand Varying Across Different Regions?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market 2025, By The Business Research Company

Cell And Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info